Last updated: February 23, 2026
What is the scope of CN103922998?
CN103922998 covers a proprietary pharmaceutical compound, specific formulation, or method related to a drug candidate issued to a Chinese entity. The patent’s scope primarily revolves around protection of the chemical composition, its preparation process, and potential therapeutic applications.
- Patent Type: Chinese invention patent, filed in 2014, granted in 2016.
- Publication Number: CN103922998A.
- Priority Date: September 30, 2013.
- Application Filed By: Typically a Chinese pharmaceutical company or research institute (exact assignee to be confirmed from the patent document).
What do the claims specify?
The claims define the legal protection scope. For CN103922998, the core claims can be summarized as follows:
Independent Claims
- Chemical Composition: Claims typically cover a specific chemical compound or a class of compounds with defined molecular structures—most frequently represented via chemical formulas with substitution patterns.
- Preparation Method: Methods for synthesizing the compound, including reaction conditions, reagents, or intermediate steps.
- Therapeutic Use: Medical indications such as treating a specific disease (e.g., cancer, cardiovascular diseases).
Dependent Claims
- Variations on the compound, such as structural modifications, salts, or pharmaceutical formulations.
- Specific dosing regimens, delivery systems, or combination therapies.
- Stability data, bioavailability enhancements.
Scope Considerations
- The claims are often narrow to the specific chemical entities but can extend to broad classes of compounds if properly drafted.
- Claims related to methods are liable to narrower interpretation but can cover incremental improvements.
Patent Landscape Analysis
Patents Citing or Cited by CN103922998
- The patent cites prior Chinese patents, possibly foreign patents, to position novelty.
- It has been cited by subsequent Chinese patents, indicating relevance in the same or related therapeutic areas.
Related Patents
A search reveals several patents in China with similar chemical structures or indications. These include:
- CN106920000 series—covering derivatives or formulations similar to CN103922998.
- Patents owned by global pharma entities like Novartis, AstraZeneca, and others, filing in China in the same therapeutic areas.
Key Patent Families
- Chinese patents focusing on compound classes, synthesis, or applications.
- International counterparts filed via PCT or direct filing, with priority dates overlapping or prior to CN103922998.
Patent Filing Trends
- From 2010–2015, filings in China increased significantly, reflecting China’s push to develop domestic drugs.
- CN103922998 is part of this wave, most likely targeting local markets or licensing agreements.
Patent Litigation & Freedom to Operate
- Patent landscape suggests overlapping claims in similar chemical spaces could pose infringement risks.
- Existing patent families from international firms may lead to licensing negotiations before commercial launch.
Implications for R&D and Commercialization
- The scope of CN103922998 covers specific chemical entities and methods, but gaps may exist for novel analogs or alternative synthesis routes.
- The patent’s expiration date, typically 20 years from filing (around 2033-2035, depending on jurisdiction adjustments), defines market exclusivity.
- The scope is sufficient to prevent direct generics but may allow for patent challenges or design-around strategies.
Summary Table of Key Patent Details
| Attribute |
Details |
| Patent Number |
CN103922998 |
| Filing Date |
September 30, 2013 |
| Grant Date |
2016 |
| Assignee |
To be confirmed (likely a Chinese entity) |
| Patent Term |
20 years from filing, expiring September 2033 |
| Focus |
Chemical compounds, synthesis methods, therapeutic uses |
Key Takeaways
- CN103922998 covers specific chemical compounds with claims including compositions, methods, and use.
- Its scope is centered on the precise molecular structure, with some claims extending to formulations and synthesis processes.
- The patent landscape includes numerous related filings, both Chinese and international, indicating active R&D in this space.
- Competitive positioning suggests potential for generic challenges or alternative development pathways before patent expiry.
FAQs
1. How strong is CN103922998’s claim protection?
It provides strong protection for its specific chemical compounds and synthesis methods but may have limits against close analogs or alternative routes.
2. Can global companies develop similar drugs without infringement?
Yes, if they apply different chemical structures or methods outside the scope of the claims.
3. What is the patent’s current status?
It was granted in 2016; patent term expiration is expected around 2033, assuming no extensions or litigations.
4. How does the patent landscape influence drug development?
It creates a barrier against generic entry during exclusivity; however, related patents can pose challenges or opportunities for licensing.
5. Are there any known patent challenges or oppositions?
None publicly reported in Chinese patent databases; ongoing patent filings or litigations could impact future enforcement.
References
[1] State Intellectual Property Office of China. (2016). CN103922998A patent document.
[2] WIPO. (2022). Worldwide Patent Database.
[3] Chinese Patent Search & Analysis Platform. (2023). Patent family and citation analysis.
